REGN · Regeneron Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $81.41B |
| P/E | 18.81 |
| Float | 98.95M |
| Beta | 0.13 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79.1 |
| Price | 785.93 |
| Change | −0.61% |
| Prev Close | 790.74 |
| Open | 803.01 |
| Day Low | 787.32 |
| Day High | 805.67 |
| Avg Vol | 1 |
| Avg $ Vol | $512.6M |
| 52W High | 859.34 |
| 52W Low | 564.00 |
| 52W Pos | 75.1% |
| From High | −8.54% |
| From Low | +39.35% |
| Max DD 1Y | −26.05% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +2.78% |
| SMA 50 | −0.62% |
| SMA 200 | +6.87% |
| RSI (14) | 57.2 |
| Vol 30D | 28.1% |
| Vol 90D | 29.1% |
| 1Y Range | 564–859 |
| Daily bars | 536 |
| Perf Week | +5.92% |
| Perf Month | +0.16% |
| Perf Quarter | +17.64% |
| Perf Half Y | +5.35% |
| Perf Year | +37.18% |
| Perf YTD | +1.24% |
| Prev Day | −0.61% |
| Clavix | B+ |
| Debt / Eq | 0.09 |
| Curr Ratio | 4.13 |
| Int Cover | 19.1× |
| FCF Margin | 34.7% |
| Rev Growth | +1.0% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 7 / 35 |
What REGN does
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies.
It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies.
The company was incorporated in 1988 and is based in Tarrytown, New York.
Clavix risk grade
regraded every trading dayREGN grades B+, 79.1 of 100. Steadiest on Macro Resilience (70), most exposed on News Sentiment (50, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 7 of 35 in Biotechnology by Clavix score.
How rough the ride is
| REGN | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.13 | 0.51 |
| Volatilityannualized | 5.0% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −26.1% | — |
| Typical daily movemedian absolute daily change | 1.08% | — |
| Days beyond ±3%of the last 252 sessions | 32 (13%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| REGN | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.13 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| REGN | |
|---|---|
| 1 week | +5.9% |
| 1 month | +0.2% |
| Year to date | +1.2% |
| 1 year | +37.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| REGN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 28 Sep |
| Average score0 most bearish, 100 most bullish | 72 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 2 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| REGN | |
|---|---|
| Revenue growthyear over year | +1.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn analysis piece argues that Regeneron's true value lies in its profit-sharing arrangement on the drug Dupixent rather than its once-flagship eye drug Eylea. It notes Regeneron's revenue continues to grow even as Eylea sales decline, crediting Dupixent as the main driver of recent strong financial results.
An analysis piece argues that Regeneron's most important growth driver is Dupixent, not Eylea. Eylea sales are declining due to competition including biosimilars, while Dupixent, developed with Sanofi and treating eczema, COPD, asthma and other conditions, has been posting strong sales growth and helping Regeneron offset Eylea's weakness.
The article states that the CHMP has recommended EU approval for an updated Libtayo (cemiplimab) dosing schedule, shifting from every three weeks to every six weeks after an initial 12-week period, across all currently approved cancer types. No further details, financial figures, or business context are provided in the article.
Regeneron's quarterly revenue rose 16.7% to $4.29 billion compared to a year earlier. It also reported positive 84-week results from a late-stage trial of Pasatru in adults with fibrodysplasia ossificans progressiva (FOP), a rare disorder where muscle and connective tissue are gradually replaced by bone, showing the drug continued to limit new abnormal bone growth and flare-ups with a consistent safety profile.
Regeneron reported 84-week data from its Phase III OPTIMA trial of Pasatru in adults with FOP, a rare disorder where muscles and connective tissue gradually turn into bone. The drug continued to prevent new bone formation and reduced flare-ups of the disease.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $126.7B | 28.75 | 0.29 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| GILD | Gilead Sciences, Inc | A- | $193.7B | 22.76 | 0.40 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| AMGN | Amgen Inc | A- | $233.8B | 26.74 | 0.44 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.